SWX:NOVNPharmaceuticals
Cosentyx Pediatric HS Approval Adds New Angle To Novartis Valuation Story
Novartis (SWX:NOVN) received FDA approval for Cosentyx to treat moderate to severe hidradenitis suppurativa in pediatric patients aged 12 years and older.
The decision makes Cosentyx the only approved IL-17A inhibitor for adolescent HS patients in the United States.
The approval adds a new age group to Cosentyx's existing indications in immunology and dermatology.
For investors tracking Novartis's immunology and dermatology efforts, this HS approval provides additional clarity on how the...